BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

Reuters

05-27

BrainStorm Cell <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

BrainStorm Cell Therapeutics Inc. $(BCLI)$ has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538468472"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538468472\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538468472?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538468472","market":"us","top_or_hot":-1,"title":"BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. <a href=\"https://laohu8.com/S/BCLI\">$(BCLI)$</a> has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with <a href=\"https://laohu8.com/S/PLUR\">Pluri Inc.</a> in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-27 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. <a href=\"https://laohu8.com/S/BCLI\">$(BCLI)$</a> has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with <a href=\"https://laohu8.com/S/PLUR\">Pluri Inc.</a> in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDLn3CN1:1","article_id":"2538468472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538468472","pubTimestamp":1748343659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BrainStorm Cell Therapeutics Inc.  has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis . The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn through these strategic relationships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-ge","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLUR":"Pluri Inc.","BCLI":"BrainStorm Cell Therapeutics Inc."},"translate_title":"BrainStorm Cell Therapeutics与Minaris合作推进NurOwn®的3b期ALS临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCLI":0.9,"PLUR":0.9},"content_text":"BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®\n    \n\n        BrainStorm Cell Therapeutics Inc. $(BCLI)$ has announced a strategic partnership with Minaris Advanced Therapies for the manufacturing of its experimental therapy, NurOwn®, in preparation for a Phase 3b clinical trial aimed at treating amyotrophic lateral sclerosis (ALS). The collaboration involves a Letter of Intent for technology transfer and clinical trial manufacturing at Minaris' facility in Allendale, New Jersey. This partnership aims to enhance BrainStorm's manufacturing capabilities in the U.S. and is part of a broader strategy to support the upcoming clinical trial. Additionally, BrainStorm's collaboration with Pluri Inc. in Israel will contribute to the production of clinical trial materials. BrainStorm emphasizes its commitment to advancing the clinical development of NurOwn® through these strategic relationships.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN96421) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}